Güleç Ceylan Gülay, Arslan Satılmış S Betül, Çavdarlı Büşranur, Semerci Gündüz C Nur
Department of Medical Genetics, Ankara City Hospital.
Department of Medical Genetics, Ankara Yıldırım Beyazıt University.
Tohoku J Exp Med. 2022 Nov 22;258(4):319-325. doi: 10.1620/tjem.2022.J087. Epub 2022 Oct 27.
Cancer is a clonal disease that develops as a result of the changes on the genetic material by various factors in micro/macro environment. It has a multi-step development process. In some cancer types, genetic factors allow this multi-step process to proceed easily. These cancer types are also called hereditary cancer syndromes. Targeted gene panels are important diagnostic methods in hereditary cancer syndromes to detect the causative variants associated with these hereditary cancer syndromes. We reviewed the data of 94 patients who applied to Ankara City Hospital Genetic Diseases Evaluation Center from March 2019 to July 2021. Qiagen familial cancer susceptibility gene panel kit was used for next generation sequencing to detect the single nucleotide variants for the targeted genes. Sixty-one genes which are associated with increased cancer risk or well characterized hereditary cancer syndromes were included to this panel. Twenty five patients (27%), including 8 males and 17 females, had pathogenic/likely pathogenic variants in 13 of the 61 genes analyzed. Forty patients (43%) had variants which were assessed as variant of unknown significant. In our study, targeted multi-gene panel was diagnostic in nearly one third of the patients with personal/familial cancer syndromes. Molecular diagnosis in familial cancer syndromes is important in terms of predictive diagnosis and family screening, as well as patient follow-up and early prophylactic surgery. The predisposition for hereditary cancer syndromes can be determined according to pre-test evaluation, figuring out the inheritance type with pedigree analysis, cancer type and the genetic analysis for appropriate susceptibility genes.
癌症是一种克隆性疾病,由微观/宏观环境中的各种因素导致遗传物质发生变化而引发。它具有多步骤的发展过程。在某些癌症类型中,遗传因素使得这一多步骤过程易于进行。这些癌症类型也被称为遗传性癌症综合征。靶向基因检测板是遗传性癌症综合征中重要的诊断方法,用于检测与这些遗传性癌症综合征相关的致病变异。我们回顾了2019年3月至2021年7月期间申请到安卡拉市医院遗传病评估中心的94例患者的数据。使用Qiagen家族性癌症易感性基因检测板试剂盒进行下一代测序,以检测靶向基因的单核苷酸变异。该检测板包含61个与癌症风险增加或特征明确的遗传性癌症综合征相关的基因。在分析的61个基因中的13个基因中,25例患者(27%),包括8名男性和17名女性,存在致病/可能致病的变异。40例患者(43%)的变异被评估为意义未明的变异。在我们的研究中,靶向多基因检测板对近三分之一的患有个人/家族性癌症综合征的患者具有诊断价值。家族性癌症综合征的分子诊断在预测性诊断和家族筛查、患者随访以及早期预防性手术方面都很重要。遗传性癌症综合征的易感性可以根据检测前评估、通过系谱分析确定遗传类型、癌症类型以及对适当的易感基因进行基因分析来确定。